Literature DB >> 25749311

Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.

Sin-Ho Jung1.   

Abstract

BACKGROUND: Phase II trials have been very widely conducted and published every year for cancer clinical research. In spite of the fast progress in design and analysis methods, single-arm two-stage design is still the most popular for phase II cancer clinical trials. Because of their small sample sizes, statistical methods based on large sample approximation are not appropriate for design and analysis of phase II trials.
METHODS: As a prospective clinical research, the analysis method of a phase II trial is predetermined at the design stage and it is analyzed during and at the end of the trial as planned by the design. The analysis method of a trial should be matched with the design method. For two-stage single arm phase II trials, Simon's method has been the standards for choosing an optimal design, but the resulting data have been analyzed and published ignoring the two-stage design aspect with small sample sizes.
CONCLUSIONS: In this article, we review analysis methods that exactly get along with the exact two-stage design method. We also discuss some statistical methods to improve the existing design and analysis methods for single-arm two-stage phase II trials.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Accrual overrun; Admissible design; Confidence interval; Two-stage design; Uniformly minimum unbiased estimator; p-Value

Mesh:

Year:  2015        PMID: 25749311      PMCID: PMC4450127          DOI: 10.1016/j.cct.2015.02.007

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  24 in total

1.  Graphical search for two-stage designs for phase II clinical trials.

Authors:  S H Jung; M Carey; K M Kim
Journal:  Control Clin Trials       Date:  2001-08

2.  On the estimation of the binomial probability in multistage clinical trials.

Authors:  Sin-Ho Jung; Kyung Mann Kim
Journal:  Stat Med       Date:  2004-03-30       Impact factor: 2.373

3.  Planned versus attained design in phase II clinical trials.

Authors:  S J Green; S Dahlberg
Journal:  Stat Med       Date:  1992-05       Impact factor: 2.373

4.  A design alternative for two-stage, phase II, multicenter cancer clinical trials.

Authors:  J E Herndon
Journal:  Control Clin Trials       Date:  1998-10

5.  Performance of adaptive designs for single-armed phase II oncology trials.

Authors:  Meinhard Kieser; Stefan Englert
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

6.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

7.  Confidence intervals following group sequential tests.

Authors:  M N Chang; P C O'Brien
Journal:  Control Clin Trials       Date:  1986-03

8.  Exact confidence intervals following a group sequential test.

Authors:  A A Tsiatis; G L Rosner; C R Mehta
Journal:  Biometrics       Date:  1984-09       Impact factor: 2.571

9.  Designs for group sequential phase II clinical trials.

Authors:  M N Chang; T M Therneau; H S Wieand; S S Cha
Journal:  Biometrics       Date:  1987-12       Impact factor: 2.571

10.  Admissible two-stage designs for phase II cancer clinical trials.

Authors:  Sin-Ho Jung; Taiyeong Lee; KyungMann Kim; Stephen L George
Journal:  Stat Med       Date:  2004-02-28       Impact factor: 2.373

View more
  5 in total

1.  Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.

Authors:  Lingyun Ji; Jennifer Whangbo; John E Levine; Todd A Alonzo
Journal:  Contemp Clin Trials       Date:  2022-07-19       Impact factor: 2.261

Review 2.  Sources of bias for single-arm phase II cancer clinical trials.

Authors:  Sin-Ho Jung
Journal:  Ann Transl Med       Date:  2022-09

3.  Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.

Authors:  Miguel Sampayo-Cordero; Bernat Miguel-Huguet; José Pérez-García; David Páez; Ángel L Guerrero-Zotano; Javier Garde-Noguera; Elena Aguirre; Esther Holgado; Elena López-Miranda; Xin Huang; Andrea Malfettone; Antonio Llombart-Cussac; Javier Cortés
Journal:  Contemp Clin Trials Commun       Date:  2020-11-28

4.  An optimal stratified Simon two-stage design.

Authors:  Deepak Parashar; Jack Bowden; Colin Starr; Lorenz Wernisch; Adrian Mander
Journal:  Pharm Stat       Date:  2016-03-02       Impact factor: 1.894

5.  Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial.

Authors:  Nut Koonrungsesomboon; Nuttapong Ngamphaiboon; Natavudh Townamchai; Pimpisa Teeyakasem; Chaiyut Charoentum; Pimlak Charoenkwan; Rungrote Natesirinilkul; Lalita Sathitsamitphong; Touch Ativitavas; Parunya Chaiyawat; Jeerawan Klangjorhor; Suradej Hongeng; Dumnoensun Pruksakorn
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.